<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962780</url>
  </required_header>
  <id_info>
    <org_study_id>6115A1-3002</org_study_id>
    <secondary_id>B1851021</secondary_id>
    <nct_id>NCT00962780</nct_id>
    <nct_alias>NCT01098370</nct_alias>
  </id_info>
  <brief_title>Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine</brief_title>
  <official_title>A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability and Immunogenicity of 2 and 3 Doses of 13vPnC in HIV-Infected Subjects 6 Years of Age and Older Who Have Not Been Previously Immunized With Pneumococcal Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, tolerability and immunogenicity of a 13-valent
      pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who
      have not been previously immunized with a pneumococcal vaccine. All subjects will receive 3
      doses of 13vPnC and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS), with
      each dose given approximately 1 month apart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
    <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
    <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants</measure>
    <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</measure>
    <time_frame>Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1</time_frame>
    <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</measure>
    <time_frame>Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</measure>
    <time_frame>Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1</time_frame>
    <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</measure>
    <time_frame>Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 3, 1 month after 23vPS Dose</time_frame>
    <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 3, 1 month after 23vPS Dose</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 3, 1 month after 23vPS Dose</time_frame>
    <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a mcOPA assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</measure>
    <time_frame>1 month after 13vPnC Dose 3, 1 month after 23vPS Dose</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1</measure>
    <time_frame>Within 14 days after 13vPnC Dose 1</time_frame>
    <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters (cm) for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged greater than (&gt;) 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Report of severe swelling was confirmed as data entry error.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2</measure>
    <time_frame>Within 14 days after 13vPnC Dose 2</time_frame>
    <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3</measure>
    <time_frame>Within 14 days after 13vPnC Dose 3</time_frame>
    <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1</measure>
    <time_frame>Within 14 days after 13vPnC Dose 1</time_frame>
    <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C except 2 participants and all reporting of severe vomiting, after 13vPnC Dose 1, were confirmed as data entry errors.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2</measure>
    <time_frame>Within 14 days after 13vPnC Dose 2</time_frame>
    <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C and all reporting of severe vomiting, after 13vPnC Dose 2, were confirmed as data entry errors.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3</measure>
    <time_frame>Within 14 days after 13vPnC Dose 3</time_frame>
    <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C except 1 participant and all reporting of severe vomiting, after 13vPnC Dose 3, were confirmed as data entry errors.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>HIV Infections</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine (13vPnC)</intervention_name>
    <description>13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent Pneumococcal Polysaccharide Vaccine (23vPS)</intervention_name>
    <description>23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Screening blood draw(s)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older

          -  Viral load &lt; 50,000 copies/mL and CD4+ T cell count &gt;= 200/uL within 6 months before
             study vaccination

          -  Receiving stable highly active antiretroviral therapy (HAART) or not currently
             receiving any antiretroviral therapy

          -  No previous vaccination with a pneumococcal vaccine

          -  Subject or parent/legal guardian able to complete an electronic diary

        Exclusion Criteria:

          -  Acquired immune deficiency syndrome (AIDS) at time of enrollment

          -  Current illicit substance and/or alcohol abuse

          -  History of active chronic viral hepatitis

          -  Previous anaphylactic reaction to a vaccine or vaccine-related component

          -  Serious chronic disorders including metastatic malignancy and end-stage renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900709</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0122</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dundee</city>
        <state>KwaZulu-Natal</state>
        <zip>3000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paarl</city>
        <zip>7626</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3002&amp;StudyName=Safety%20and%20Immunogenicity%20of%2013-Valent%20pneumococcal%20conjugate%20vaccine%20%2813vPnC%29%20in%20HIV-Infected%20Subjects%206%20Years%20of%20Age%20or%20Older%20who</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>August 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2009</study_first_posted>
  <results_first_submitted>March 17, 2014</results_first_submitted>
  <results_first_submitted_qc>November 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2014</results_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>13-valent pneumococcal conjugate vaccine</keyword>
  <keyword>23-valent pneumococcal polysaccharide vaccine</keyword>
  <keyword>human immunodeficiency virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC, 23vPS (Pediatric Participants)</title>
          <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
        </group>
        <group group_id="P2">
          <title>13vPnC, 23vPS (Adult Participants)</title>
          <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 13vPnC Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 13vPnC Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 13vPnC Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated 23vPS Dose</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all enrolled participants who received at least 1 dose of investigational product.</population>
      <group_list>
        <group group_id="B1">
          <title>13vPnC, 23vPS (Pediatric Participants)</title>
          <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
        </group>
        <group group_id="B2">
          <title>13vPnC, 23vPS (Adult Participants)</title>
          <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="301"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.3" spread="3.04"/>
                    <measurement group_id="B2" value="41.2" spread="8.45"/>
                    <measurement group_id="B3" value="25.8" spread="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
        <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
        <population>Evaluable immunogenicity population:eligible participants who received vaccination as assigned;had blood drawn within pre-specified time-frames;had at least 1 valid, determinate assay result; had no major protocol violation. N (number of participants analyzed)=participants evaluable for this measure, n=participants evaluable for specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
          <population>Evaluable immunogenicity population:eligible participants who received vaccination as assigned;had blood drawn within pre-specified time-frames;had at least 1 valid, determinate assay result; had no major protocol violation. N (number of participants analyzed)=participants evaluable for this measure, n=participants evaluable for specified serotype.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n = 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.99" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n = 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="1.00" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n = 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="1.03" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n = 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.97" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n = 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.97" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n = 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="1.01" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n = 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="1.05" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n = 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="1.01" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n = 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="1.00" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n = 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.96" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n = 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.96" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n = 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="1.01" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n = 258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="1.03" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants</title>
        <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
        <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies all participants who were evaluable for this measure and &quot;n&quot; signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants</title>
          <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies all participants who were evaluable for this measure and &quot;n&quot; signifies all participants who were evaluable for specified serotype for each treatment arm, respectively.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: 13vPnC Dose 2 (n = 120, 128, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" lower_limit="3.30" upper_limit="4.57"/>
                    <measurement group_id="O2" value="3.95" lower_limit="3.23" upper_limit="4.85"/>
                    <measurement group_id="O3" value="3.92" lower_limit="3.44" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: 13vPnC Dose 3 (n = 120, 128, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="3.56" upper_limit="4.83"/>
                    <measurement group_id="O2" value="3.92" lower_limit="3.21" upper_limit="4.79"/>
                    <measurement group_id="O3" value="4.03" lower_limit="3.55" upper_limit="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 13vPnC Dose 2 (n = 118, 120, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="1.25" upper_limit="1.74"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.81" upper_limit="1.16"/>
                    <measurement group_id="O3" value="1.19" lower_limit="1.05" upper_limit="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 13vPnC Dose 3 (n = 118, 120, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.26" upper_limit="1.76"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.88" upper_limit="1.27"/>
                    <measurement group_id="O3" value="1.25" lower_limit="1.11" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 13vPnC Dose 2 (n = 127, 130, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" lower_limit="2.54" upper_limit="3.69"/>
                    <measurement group_id="O2" value="2.97" lower_limit="2.40" upper_limit="3.67"/>
                    <measurement group_id="O3" value="3.01" lower_limit="2.62" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 13vPnC Dose 3 (n = 127, 130, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" lower_limit="2.84" upper_limit="3.97"/>
                    <measurement group_id="O2" value="3.19" lower_limit="2.59" upper_limit="3.91"/>
                    <measurement group_id="O3" value="3.27" lower_limit="2.87" upper_limit="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: 13vPnC Dose 2 (n = 126, 131, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.52" lower_limit="3.78" upper_limit="5.39"/>
                    <measurement group_id="O2" value="5.77" lower_limit="4.83" upper_limit="6.89"/>
                    <measurement group_id="O3" value="5.12" lower_limit="4.51" upper_limit="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: 13vPnC Dose 3 (n = 126, 131, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.84" lower_limit="4.12" upper_limit="5.70"/>
                    <measurement group_id="O2" value="5.53" lower_limit="4.63" upper_limit="6.61"/>
                    <measurement group_id="O3" value="5.18" lower_limit="4.60" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: 13vPnC Dose 2 (n = 119, 130, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" lower_limit="6.46" upper_limit="9.08"/>
                    <measurement group_id="O2" value="7.03" lower_limit="5.71" upper_limit="8.67"/>
                    <measurement group_id="O3" value="7.33" lower_limit="6.40" upper_limit="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: 13vPnC Dose 3 (n = 119, 130, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.97" lower_limit="6.81" upper_limit="9.33"/>
                    <measurement group_id="O2" value="7.04" lower_limit="5.74" upper_limit="8.64"/>
                    <measurement group_id="O3" value="7.47" lower_limit="6.56" upper_limit="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: 13vPnC Dose 2 (n = 127, 130, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.43" lower_limit="9.45" upper_limit="13.84"/>
                    <measurement group_id="O2" value="7.93" lower_limit="6.51" upper_limit="9.65"/>
                    <measurement group_id="O3" value="9.50" lower_limit="8.28" upper_limit="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: 13vPnC Dose 3 (n = 127, 130, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.94" lower_limit="10.01" upper_limit="14.24"/>
                    <measurement group_id="O2" value="8.28" lower_limit="6.78" upper_limit="10.11"/>
                    <measurement group_id="O3" value="9.92" lower_limit="8.67" upper_limit="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: 13vPnC Dose 2 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="3.67" upper_limit="4.92"/>
                    <measurement group_id="O2" value="5.78" lower_limit="4.81" upper_limit="6.95"/>
                    <measurement group_id="O3" value="4.96" lower_limit="4.41" upper_limit="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: 13vPnC Dose 3 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" lower_limit="4.38" upper_limit="5.82"/>
                    <measurement group_id="O2" value="5.90" lower_limit="4.95" upper_limit="7.04"/>
                    <measurement group_id="O3" value="5.46" lower_limit="4.88" upper_limit="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: 13vPnC Dose 2 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" lower_limit="4.18" upper_limit="5.54"/>
                    <measurement group_id="O2" value="5.14" lower_limit="4.27" upper_limit="6.19"/>
                    <measurement group_id="O3" value="4.98" lower_limit="4.43" upper_limit="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: 13vPnC Dose 3 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" lower_limit="4.35" upper_limit="5.70"/>
                    <measurement group_id="O2" value="5.48" lower_limit="4.59" upper_limit="6.55"/>
                    <measurement group_id="O3" value="5.23" lower_limit="4.67" upper_limit="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: 13vPnC Dose 2 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.60" lower_limit="8.76" upper_limit="15.35"/>
                    <measurement group_id="O2" value="15.14" lower_limit="11.64" upper_limit="19.71"/>
                    <measurement group_id="O3" value="13.27" lower_limit="10.96" upper_limit="16.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: 13vPnC Dose 3 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.62" lower_limit="9.75" upper_limit="16.33"/>
                    <measurement group_id="O2" value="15.13" lower_limit="11.80" upper_limit="19.40"/>
                    <measurement group_id="O3" value="13.83" lower_limit="11.57" upper_limit="16.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: 13vPnC Dose 2 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" lower_limit="3.12" upper_limit="4.60"/>
                    <measurement group_id="O2" value="5.33" lower_limit="4.34" upper_limit="6.54"/>
                    <measurement group_id="O3" value="4.50" lower_limit="3.91" upper_limit="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: 13vPnC Dose 3 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" lower_limit="3.19" upper_limit="4.60"/>
                    <measurement group_id="O2" value="5.18" lower_limit="4.27" upper_limit="6.28"/>
                    <measurement group_id="O3" value="4.46" lower_limit="3.90" upper_limit="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: 13vPnC Dose 2 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.38" lower_limit="12.20" upper_limit="16.96"/>
                    <measurement group_id="O2" value="13.19" lower_limit="11.06" upper_limit="15.75"/>
                    <measurement group_id="O3" value="13.77" lower_limit="12.21" upper_limit="15.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: 13vPnC Dose 3 (n = 128, 131, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.19" lower_limit="12.17" upper_limit="16.54"/>
                    <measurement group_id="O2" value="13.18" lower_limit="11.11" upper_limit="15.62"/>
                    <measurement group_id="O3" value="13.67" lower_limit="12.20" upper_limit="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: 13vPnC Dose 2 (n = 124, 128, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" lower_limit="4.63" upper_limit="7.21"/>
                    <measurement group_id="O2" value="5.34" lower_limit="4.17" upper_limit="6.84"/>
                    <measurement group_id="O3" value="5.55" lower_limit="4.71" upper_limit="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: 13vPnC Dose 3 (n = 124, 128, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" lower_limit="4.98" upper_limit="7.44"/>
                    <measurement group_id="O2" value="5.67" lower_limit="4.47" upper_limit="7.18"/>
                    <measurement group_id="O3" value="5.87" lower_limit="5.03" upper_limit="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: 13vPnC Dose 2 (n = 127, 131, 258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" lower_limit="5.30" upper_limit="7.85"/>
                    <measurement group_id="O2" value="6.10" lower_limit="4.86" upper_limit="7.66"/>
                    <measurement group_id="O3" value="6.27" lower_limit="5.40" upper_limit="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: 13vPnC Dose 3 (n = 127, 131, 258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" lower_limit="5.55" upper_limit="7.94"/>
                    <measurement group_id="O2" value="7.06" lower_limit="5.65" upper_limit="8.82"/>
                    <measurement group_id="O3" value="6.85" lower_limit="5.94" upper_limit="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants</title>
        <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants</title>
          <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws for each treatment arm, respectively.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: 13vPnC Dose 2 (n = 126, 127, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="37.2" upper_limit="70.0"/>
                    <measurement group_id="O2" value="54" lower_limit="38.7" upper_limit="74.2"/>
                    <measurement group_id="O3" value="52" lower_limit="41.8" upper_limit="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: 13vPnC Dose 3 (n = 126, 127, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="51.6" upper_limit="91.4"/>
                    <measurement group_id="O2" value="69" lower_limit="51.3" upper_limit="92.0"/>
                    <measurement group_id="O3" value="69" lower_limit="56.1" upper_limit="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 13vPnC Dose 2 (n = 127, 129, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="64.1" upper_limit="102.0"/>
                    <measurement group_id="O2" value="48" lower_limit="37.9" upper_limit="61.5"/>
                    <measurement group_id="O3" value="62" lower_limit="52.6" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 13vPnC Dose 3 (n = 127, 129, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="94.5" upper_limit="137.8"/>
                    <measurement group_id="O2" value="79" lower_limit="62.1" upper_limit="99.9"/>
                    <measurement group_id="O3" value="95" lower_limit="81.3" upper_limit="110.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 13vPnC Dose 2 (n = 117, 126, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2509" lower_limit="1922.3" upper_limit="3274.2"/>
                    <measurement group_id="O2" value="1620" lower_limit="1211.2" upper_limit="2167.4"/>
                    <measurement group_id="O3" value="2000" lower_limit="1639.8" upper_limit="2439.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 13vPnC Dose 3 (n = 117, 126, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3246" lower_limit="2697.1" upper_limit="3906.3"/>
                    <measurement group_id="O2" value="1944" lower_limit="1465.3" upper_limit="2579.7"/>
                    <measurement group_id="O3" value="2488" lower_limit="2092.1" upper_limit="2959.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: 13vPnC Dose 2 (n = 122, 124, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" lower_limit="109.2" upper_limit="232.2"/>
                    <measurement group_id="O2" value="104" lower_limit="69.1" upper_limit="156.9"/>
                    <measurement group_id="O3" value="129" lower_limit="97.3" upper_limit="169.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: 13vPnC Dose 3 (n = 122, 124, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" lower_limit="191.3" upper_limit="371.5"/>
                    <measurement group_id="O2" value="142" lower_limit="97.5" upper_limit="206.7"/>
                    <measurement group_id="O3" value="194" lower_limit="150.8" upper_limit="249.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: 13vPnC Dose 2 (n = 125, 124, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5560" lower_limit="4378.4" upper_limit="7060.9"/>
                    <measurement group_id="O2" value="2425" lower_limit="1790.7" upper_limit="3284.5"/>
                    <measurement group_id="O3" value="3678" lower_limit="3016.2" upper_limit="4485.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: 13vPnC Dose 3 (n = 125, 124, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7758" lower_limit="6314.2" upper_limit="9531.2"/>
                    <measurement group_id="O2" value="3239" lower_limit="2488.5" upper_limit="4215.9"/>
                    <measurement group_id="O3" value="5022" lower_limit="4216.8" upper_limit="5979.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: 13vPnC Dose 2 (n = 121, 128, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5449" lower_limit="4365.1" upper_limit="6801.1"/>
                    <measurement group_id="O2" value="2724" lower_limit="2004.8" upper_limit="3701.0"/>
                    <measurement group_id="O3" value="3815" lower_limit="3140.9" upper_limit="4634.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: 13vPnC Dose 3 (n = 121, 128, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7151" lower_limit="5828.2" upper_limit="8773.9"/>
                    <measurement group_id="O2" value="3723" lower_limit="2771.1" upper_limit="5002.5"/>
                    <measurement group_id="O3" value="5113" lower_limit="4250.1" upper_limit="6150.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: 13vPnC Dose 2 (n = 125, 127, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3494" lower_limit="2772.8" upper_limit="4403.3"/>
                    <measurement group_id="O2" value="2255" lower_limit="1739.6" upper_limit="2923.6"/>
                    <measurement group_id="O3" value="2802" lower_limit="2352.6" upper_limit="3338.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: 13vPnC Dose 3 (n = 125, 127, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4638" lower_limit="3889.7" upper_limit="5529.4"/>
                    <measurement group_id="O2" value="2702" lower_limit="2130.3" upper_limit="3428.2"/>
                    <measurement group_id="O3" value="3533" lower_limit="3037.4" upper_limit="4108.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: 13vPnC Dose 2 (n = 118, 127, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3339" lower_limit="2461.4" upper_limit="4530.3"/>
                    <measurement group_id="O2" value="1432" lower_limit="998.6" upper_limit="2054.9"/>
                    <measurement group_id="O3" value="2153" lower_limit="1690.3" upper_limit="2743.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: 13vPnC Dose 3 (n = 118, 127, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4714" lower_limit="3731.5" upper_limit="5955.4"/>
                    <measurement group_id="O2" value="2004" lower_limit="1416.5" upper_limit="2836.1"/>
                    <measurement group_id="O3" value="3026" lower_limit="2434.3" upper_limit="3761.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: 13vPnC Dose 2 (n = 117, 127, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3704" lower_limit="2906.5" upper_limit="4719.5"/>
                    <measurement group_id="O2" value="1342" lower_limit="1010.1" upper_limit="1782.1"/>
                    <measurement group_id="O3" value="2183" lower_limit="1792.2" upper_limit="2659.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: 13vPnC Dose 3 (n = 117, 127, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3963" lower_limit="3195.8" upper_limit="4914.2"/>
                    <measurement group_id="O2" value="1480" lower_limit="1150.3" upper_limit="1903.9"/>
                    <measurement group_id="O3" value="2373" lower_limit="1988.4" upper_limit="2832.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: 13vPnC Dose 2 (n = 117, 121, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4635" lower_limit="3609.7" upper_limit="5951.8"/>
                    <measurement group_id="O2" value="1349" lower_limit="947.0" upper_limit="1921.5"/>
                    <measurement group_id="O3" value="2475" lower_limit="1965.7" upper_limit="3115.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: 13vPnC Dose 3 (n = 117, 121, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5579" lower_limit="4423.7" upper_limit="7036.9"/>
                    <measurement group_id="O2" value="1787" lower_limit="1272.8" upper_limit="2508.5"/>
                    <measurement group_id="O3" value="3127" lower_limit="2515.2" upper_limit="3888.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: 13vPnC Dose 2 (n = 125, 127, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="684" lower_limit="519.2" upper_limit="902.1"/>
                    <measurement group_id="O2" value="458" lower_limit="332.5" upper_limit="631.2"/>
                    <measurement group_id="O3" value="559" lower_limit="452.3" upper_limit="690.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: 13vPnC Dose 3 (n = 125, 127, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1002" lower_limit="814.5" upper_limit="1232.3"/>
                    <measurement group_id="O2" value="613" lower_limit="465.6" upper_limit="806.4"/>
                    <measurement group_id="O3" value="782" lower_limit="657.2" upper_limit="930.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: 13vPnC Dose 2 (n = 122, 118, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="717" lower_limit="495.6" upper_limit="1036.7"/>
                    <measurement group_id="O2" value="315" lower_limit="196.7" upper_limit="506.0"/>
                    <measurement group_id="O3" value="479" lower_limit="354.4" upper_limit="646.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: 13vPnC Dose 3 (n = 122, 118, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1152" lower_limit="864.2" upper_limit="1535.0"/>
                    <measurement group_id="O2" value="597" lower_limit="397.9" upper_limit="897.1"/>
                    <measurement group_id="O3" value="834" lower_limit="650.1" upper_limit="1070.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: 13vPnC Dose 2 (n = 120, 126, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1477" lower_limit="1086.2" upper_limit="2008.2"/>
                    <measurement group_id="O2" value="409" lower_limit="271.9" upper_limit="614.0"/>
                    <measurement group_id="O3" value="765" lower_limit="585.2" upper_limit="999.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: 13vPnC Dose 3 (n = 120, 126, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2327" lower_limit="1844.2" upper_limit="2935.9"/>
                    <measurement group_id="O2" value="671" lower_limit="449.8" upper_limit="1000.3"/>
                    <measurement group_id="O3" value="1231" lower_limit="963.0" upper_limit="1572.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
        <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n = 126, 127, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.13" upper_limit="1.61"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.09" upper_limit="1.51"/>
                    <measurement group_id="O3" value="1.3" lower_limit="1.16" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n = 127, 129, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.25" upper_limit="1.59"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.45" upper_limit="1.83"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.40" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n = 117, 126, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.10" upper_limit="1.52"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.07" upper_limit="1.34"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.13" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n = 122, 124, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.36" upper_limit="2.06"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.17" upper_limit="1.59"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.33" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n = 125, 124, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.22" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.15" upper_limit="1.55"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.23" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n = 121, 128, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.18" upper_limit="1.46"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.20" upper_limit="1.56"/>
                    <measurement group_id="O3" value="1.3" lower_limit="1.23" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n = 125, 127, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.15" upper_limit="1.53"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.03" upper_limit="1.40"/>
                    <measurement group_id="O3" value="1.3" lower_limit="1.14" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n = 118, 127, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.16" upper_limit="1.72"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.18" upper_limit="1.65"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.24" upper_limit="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n = 117, 127, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.95" upper_limit="1.20"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.98" upper_limit="1.24"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.00" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n = 117, 121, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.10" upper_limit="1.32"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.08" upper_limit="1.63"/>
                    <measurement group_id="O3" value="1.3" lower_limit="1.13" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n = 125, 127, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.27" upper_limit="1.68"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.18" upper_limit="1.52"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.27" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n = 122, 118, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.31" upper_limit="1.97"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.45" upper_limit="2.48"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.48" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n = 120, 126, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.31" upper_limit="1.90"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.34" upper_limit="2.02"/>
                    <measurement group_id="O3" value="1.6" lower_limit="1.40" upper_limit="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
        <time_frame>1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n = 120, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="1.01" upper_limit="1.13"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.93" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n = 118, 120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.95" upper_limit="1.08"/>
                    <measurement group_id="O2" value="1.09" lower_limit="1.02" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n = 127, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="1.02" upper_limit="1.18"/>
                    <measurement group_id="O2" value="1.07" lower_limit="1.00" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n = 126, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="1.01" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.91" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n = 119, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.96" upper_limit="1.12"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.95" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n = 127, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.99" upper_limit="1.10"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.99" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n = 128, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="1.12" upper_limit="1.27"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.95" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n = 128, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.98" upper_limit="1.09"/>
                    <measurement group_id="O2" value="1.07" lower_limit="1.02" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n = 128, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="1.02" upper_limit="1.16"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.95" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n = 128, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.96" upper_limit="1.07"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.93" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n = 128, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.93" upper_limit="1.04"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.96" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n = 124, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.98" upper_limit="1.13"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.99" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n = 127, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.96" upper_limit="1.11"/>
                    <measurement group_id="O2" value="1.16" lower_limit="1.07" upper_limit="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</title>
        <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
        <time_frame>Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the before and 1 month after 13vPnC Dose 1 blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</title>
          <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the before and 1 month after 13vPnC Dose 1 blood draws for each treatment arm, respectively.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: Before 13vPnC Dose 1 (n=78,122,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.72" upper_limit="1.48"/>
                    <measurement group_id="O2" value="0.82" lower_limit="0.63" upper_limit="1.06"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.73" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: After 13vPnC Dose 1 (n=78,122,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" lower_limit="2.97" upper_limit="4.80"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.19" upper_limit="5.01"/>
                    <measurement group_id="O3" value="3.91" lower_limit="3.32" upper_limit="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Before 13vPnC Dose 1 (n=99,127,226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.62" upper_limit="1.11"/>
                    <measurement group_id="O2" value="0.47" lower_limit="0.37" upper_limit="0.58"/>
                    <measurement group_id="O3" value="0.60" lower_limit="0.50" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: After 13vPnC Dose 1 (n=99,127,226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.99" upper_limit="1.58"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.62" upper_limit="0.92"/>
                    <measurement group_id="O3" value="0.94" lower_limit="0.81" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Before 13vPnC Dose 1 (n=95,127,222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.14" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.35" lower_limit="0.28" upper_limit="0.45"/>
                    <measurement group_id="O3" value="0.27" lower_limit="0.22" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: After 13vPnC Dose 1 (n=95,127,222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" lower_limit="1.97" upper_limit="3.50"/>
                    <measurement group_id="O2" value="2.91" lower_limit="2.26" upper_limit="3.75"/>
                    <measurement group_id="O3" value="2.79" lower_limit="2.31" upper_limit="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: Before 13vPnC Dose 1 (n=122,137,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" lower_limit="3.42" upper_limit="5.12"/>
                    <measurement group_id="O2" value="3.38" lower_limit="2.84" upper_limit="4.02"/>
                    <measurement group_id="O3" value="3.74" lower_limit="3.28" upper_limit="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: After 13vPnC Dose 1 (n=122,137,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" lower_limit="3.98" upper_limit="5.80"/>
                    <measurement group_id="O2" value="5.53" lower_limit="4.63" upper_limit="6.61"/>
                    <measurement group_id="O3" value="5.18" lower_limit="4.55" upper_limit="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: Before 13vPnC Dose 1 (n=99,136,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" lower_limit="5.19" upper_limit="7.45"/>
                    <measurement group_id="O2" value="2.67" lower_limit="2.24" upper_limit="3.18"/>
                    <measurement group_id="O3" value="3.81" lower_limit="3.32" upper_limit="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: After 13vPnC Dose 1 (n=99,136,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" lower_limit="6.07" upper_limit="8.79"/>
                    <measurement group_id="O2" value="6.77" lower_limit="5.38" upper_limit="8.51"/>
                    <measurement group_id="O3" value="6.99" lower_limit="6.00" upper_limit="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: Before 13vPnC Dose 1 (n=131,134,265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" lower_limit="4.59" upper_limit="6.64"/>
                    <measurement group_id="O2" value="3.23" lower_limit="2.69" upper_limit="3.88"/>
                    <measurement group_id="O3" value="4.21" lower_limit="3.69" upper_limit="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: After 13vPnC Dose 1 (n=131,134,265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.26" lower_limit="8.37" upper_limit="12.58"/>
                    <measurement group_id="O2" value="7.29" lower_limit="5.81" upper_limit="9.15"/>
                    <measurement group_id="O3" value="8.63" lower_limit="7.41" upper_limit="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: Before 13vPnC Dose 1 (n=111,134,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.63" upper_limit="1.14"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.94" upper_limit="1.37"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.84" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: After 13vPnC Dose 1 (n=111,134,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" lower_limit="3.68" upper_limit="5.11"/>
                    <measurement group_id="O2" value="5.57" lower_limit="4.57" upper_limit="6.78"/>
                    <measurement group_id="O3" value="4.97" lower_limit="4.36" upper_limit="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: Before 13vPnC Dose 1 (n=129,137,266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" lower_limit="1.74" upper_limit="2.54"/>
                    <measurement group_id="O2" value="1.56" lower_limit="1.30" upper_limit="1.86"/>
                    <measurement group_id="O3" value="1.80" lower_limit="1.58" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: After 13vPnC Dose 1 (n=129,137,266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" lower_limit="4.08" upper_limit="5.57"/>
                    <measurement group_id="O2" value="5.16" lower_limit="4.24" upper_limit="6.27"/>
                    <measurement group_id="O3" value="4.97" lower_limit="4.38" upper_limit="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: Before 13vPnC Dose 1 (n=113,136,249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.57" upper_limit="1.03"/>
                    <measurement group_id="O2" value="2.45" lower_limit="1.94" upper_limit="3.09"/>
                    <measurement group_id="O3" value="1.44" lower_limit="1.18" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: After 13vPnC Dose 1 (n=113,136,249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.04" lower_limit="8.48" upper_limit="17.10"/>
                    <measurement group_id="O2" value="16.46" lower_limit="12.38" upper_limit="21.90"/>
                    <measurement group_id="O3" value="14.28" lower_limit="11.44" upper_limit="17.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: Before 13vPnC Dose 1 (n=127,134,261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.52" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.69" upper_limit="1.04"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.64" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: After 13vPnC Dose 1 (n=127,134,261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="3.14" upper_limit="4.91"/>
                    <measurement group_id="O2" value="5.55" lower_limit="4.51" upper_limit="6.84"/>
                    <measurement group_id="O3" value="4.69" lower_limit="4.02" upper_limit="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: Before 13vPnC Dose 1 (n=133,137,270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" lower_limit="6.34" upper_limit="8.90"/>
                    <measurement group_id="O2" value="4.78" lower_limit="4.04" upper_limit="5.66"/>
                    <measurement group_id="O3" value="5.97" lower_limit="5.29" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: After 13vPnC Dose 1 (n=133,137,270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.28" lower_limit="11.11" upper_limit="15.87"/>
                    <measurement group_id="O2" value="13.03" lower_limit="10.75" upper_limit="15.80"/>
                    <measurement group_id="O3" value="13.15" lower_limit="11.54" upper_limit="14.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: Before 13vPnC Dose 1 (n=93,126,219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="1.06" upper_limit="1.75"/>
                    <measurement group_id="O2" value="1.36" lower_limit="1.07" upper_limit="1.73"/>
                    <measurement group_id="O3" value="1.36" lower_limit="1.14" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: After 13vPnC Dose 1 (n=93,126,219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" lower_limit="3.55" upper_limit="6.02"/>
                    <measurement group_id="O2" value="4.98" lower_limit="3.74" upper_limit="6.62"/>
                    <measurement group_id="O3" value="4.82" lower_limit="3.96" upper_limit="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: Before 13vPnC Dose 1 (n=126,137,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" lower_limit="1.83" upper_limit="2.86"/>
                    <measurement group_id="O2" value="1.61" lower_limit="1.31" upper_limit="1.96"/>
                    <measurement group_id="O3" value="1.90" lower_limit="1.64" upper_limit="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: After 13vPnC Dose 1 (n=126,137,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" lower_limit="4.66" upper_limit="6.86"/>
                    <measurement group_id="O2" value="5.30" lower_limit="4.16" upper_limit="6.75"/>
                    <measurement group_id="O3" value="5.47" lower_limit="4.68" upper_limit="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.</description>
        <time_frame>Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the before and 1 month after 13vPnC Dose 1 blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the before and 1 month after 13vPnC Dose 1 blood draws for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n = 78, 122, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" lower_limit="2.70" upper_limit="4.99"/>
                    <measurement group_id="O2" value="4.88" lower_limit="3.87" upper_limit="6.15"/>
                    <measurement group_id="O3" value="4.37" lower_limit="3.63" upper_limit="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n = 99, 127, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.27" upper_limit="1.79"/>
                    <measurement group_id="O2" value="1.62" lower_limit="1.43" upper_limit="1.83"/>
                    <measurement group_id="O3" value="1.57" lower_limit="1.42" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n = 95, 127, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.02" lower_limit="10.55" upper_limit="18.62"/>
                    <measurement group_id="O2" value="8.29" lower_limit="6.55" upper_limit="10.49"/>
                    <measurement group_id="O3" value="10.38" lower_limit="8.64" upper_limit="12.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n = 122, 137, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.06" upper_limit="1.25"/>
                    <measurement group_id="O2" value="1.64" lower_limit="1.44" upper_limit="1.85"/>
                    <measurement group_id="O3" value="1.38" lower_limit="1.28" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n = 99, 136, 235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="1.02" upper_limit="1.35"/>
                    <measurement group_id="O2" value="2.54" lower_limit="2.09" upper_limit="3.07"/>
                    <measurement group_id="O3" value="1.83" lower_limit="1.60" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n = 131, 134, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" lower_limit="1.55" upper_limit="2.22"/>
                    <measurement group_id="O2" value="2.26" lower_limit="1.87" upper_limit="2.72"/>
                    <measurement group_id="O3" value="2.05" lower_limit="1.80" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n = 111, 134, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" lower_limit="3.92" upper_limit="6.65"/>
                    <measurement group_id="O2" value="4.90" lower_limit="3.99" upper_limit="6.03"/>
                    <measurement group_id="O3" value="4.99" lower_limit="4.24" upper_limit="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n = 129, 137, 266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" lower_limit="1.97" upper_limit="2.61"/>
                    <measurement group_id="O2" value="3.32" lower_limit="2.76" upper_limit="3.99"/>
                    <measurement group_id="O3" value="2.76" lower_limit="2.45" upper_limit="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n = 113, 136, 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.79" lower_limit="11.84" upper_limit="21.05"/>
                    <measurement group_id="O2" value="6.73" lower_limit="5.17" upper_limit="8.76"/>
                    <measurement group_id="O3" value="9.91" lower_limit="8.11" upper_limit="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n = 127, 134, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" lower_limit="4.64" upper_limit="7.55"/>
                    <measurement group_id="O2" value="6.55" lower_limit="5.23" upper_limit="8.20"/>
                    <measurement group_id="O3" value="6.23" lower_limit="5.29" upper_limit="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n = 133, 137, 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" lower_limit="1.55" upper_limit="2.02"/>
                    <measurement group_id="O2" value="2.73" lower_limit="2.31" upper_limit="3.21"/>
                    <measurement group_id="O3" value="2.20" lower_limit="1.98" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n = 93, 126, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" lower_limit="2.71" upper_limit="4.25"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2.96" upper_limit="4.52"/>
                    <measurement group_id="O3" value="3.54" lower_limit="3.04" upper_limit="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n = 126, 137, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" lower_limit="2.02" upper_limit="3.02"/>
                    <measurement group_id="O2" value="3.30" lower_limit="2.71" upper_limit="4.03"/>
                    <measurement group_id="O3" value="2.87" lower_limit="2.49" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</title>
        <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the before and 1 month after 13vPnC Dose 1 blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</title>
          <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the before and 1 month after 13vPnC Dose 1 blood draws for each treatment arm, respectively.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: Before 13vPnC Dose 1 (n=129,127,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4.3" upper_limit="5.8"/>
                    <measurement group_id="O2" value="5" lower_limit="4.3" upper_limit="5.2"/>
                    <measurement group_id="O3" value="5" lower_limit="4.4" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: After 13vPnC Dose 1 (n=129,127,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="35.3" upper_limit="68.1"/>
                    <measurement group_id="O2" value="57" lower_limit="41.6" upper_limit="79.3"/>
                    <measurement group_id="O3" value="53" lower_limit="42.2" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Before 13vPnC Dose 1 (n=126,128,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6.6" upper_limit="10.8"/>
                    <measurement group_id="O2" value="5" lower_limit="4.5" upper_limit="5.8"/>
                    <measurement group_id="O3" value="7" lower_limit="5.7" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: After 13vPnC Dose 1 (n=126,128,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="31.7" upper_limit="52.6"/>
                    <measurement group_id="O2" value="21" lower_limit="16.3" upper_limit="27.1"/>
                    <measurement group_id="O3" value="29" lower_limit="24.3" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Before 13vPnC Dose 1 (n=108,119,227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="15.2" upper_limit="41.7"/>
                    <measurement group_id="O2" value="27" lower_limit="17.0" upper_limit="42.1"/>
                    <measurement group_id="O3" value="26" lower_limit="18.6" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: After 13vPnC Dose 1 (n=108,119,227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2247" lower_limit="1611.9" upper_limit="3131.4"/>
                    <measurement group_id="O2" value="1372" lower_limit="958.8" upper_limit="1963.7"/>
                    <measurement group_id="O3" value="1735" lower_limit="1356.9" upper_limit="2218.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: Before 13vPnC Dose 1 (n=125,122,247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4.5" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6" lower_limit="4.8" upper_limit="6.8"/>
                    <measurement group_id="O3" value="6" lower_limit="4.9" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: After 13vPnC Dose 1 (n=125,122,247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="52.5" upper_limit="118.0"/>
                    <measurement group_id="O2" value="123" lower_limit="81.8" upper_limit="186.3"/>
                    <measurement group_id="O3" value="98" lower_limit="73.7" upper_limit="131.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: Before 13vPnC Dose 1 (n=99,98,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" lower_limit="84.4" upper_limit="292.5"/>
                    <measurement group_id="O2" value="61" lower_limit="35.1" upper_limit="106.8"/>
                    <measurement group_id="O3" value="98" lower_limit="64.6" upper_limit="149.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: After 13vPnC Dose 1 (n=99,98,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3480" lower_limit="2460.1" upper_limit="4921.8"/>
                    <measurement group_id="O2" value="1543" lower_limit="984.4" upper_limit="2418.5"/>
                    <measurement group_id="O3" value="2322" lower_limit="1743.1" upper_limit="3092.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: Before 13vPnC Dose 1 (n=101,120,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279" lower_limit="155.5" upper_limit="501.1"/>
                    <measurement group_id="O2" value="231" lower_limit="143.4" upper_limit="372.5"/>
                    <measurement group_id="O3" value="252" lower_limit="174.1" upper_limit="364.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: After 13vPnC Dose 1 (n=101,120,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3852" lower_limit="2888.3" upper_limit="5137.8"/>
                    <measurement group_id="O2" value="2099" lower_limit="1455.6" upper_limit="3028.2"/>
                    <measurement group_id="O3" value="2771" lower_limit="2179.2" upper_limit="3522.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: Before 13vPnC Dose 1 (n=110,113,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416" lower_limit="253.5" upper_limit="682.9"/>
                    <measurement group_id="O2" value="38" lower_limit="22.9" upper_limit="64.6"/>
                    <measurement group_id="O3" value="124" lower_limit="84.3" upper_limit="183.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: After 13vPnC Dose 1 (n=110,113,223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3775" lower_limit="3019.4" upper_limit="4720.1"/>
                    <measurement group_id="O2" value="2005" lower_limit="1443.9" upper_limit="2783.1"/>
                    <measurement group_id="O3" value="2739" lower_limit="2237.5" upper_limit="3353.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: Before 13vPnC Dose 1 (n=109,117,226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" lower_limit="87.2" upper_limit="266.2"/>
                    <measurement group_id="O2" value="69" lower_limit="40.7" upper_limit="117.2"/>
                    <measurement group_id="O3" value="101" lower_limit="68.8" upper_limit="148.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: After 13vPnC Dose 1 (n=109,117,226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2533" lower_limit="1822.7" upper_limit="3520.3"/>
                    <measurement group_id="O2" value="1231" lower_limit="836.1" upper_limit="1812.2"/>
                    <measurement group_id="O3" value="1743" lower_limit="1347.0" upper_limit="2256.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: Before 13vPnC Dose 1 (n=107,126,233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328" lower_limit="201.4" upper_limit="535.5"/>
                    <measurement group_id="O2" value="123" lower_limit="79.6" upper_limit="191.4"/>
                    <measurement group_id="O3" value="193" lower_limit="139.0" upper_limit="269.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: After 13vPnC Dose 1 (n=107,126,233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3571" lower_limit="2772.2" upper_limit="4600.1"/>
                    <measurement group_id="O2" value="1277" lower_limit="944.9" upper_limit="1725.8"/>
                    <measurement group_id="O3" value="2048" lower_limit="1660.8" upper_limit="2524.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: Before 13vPnC Dose 1 (n=95,120,215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="21.9" upper_limit="79.0"/>
                    <measurement group_id="O2" value="25" lower_limit="15.5" upper_limit="39.6"/>
                    <measurement group_id="O3" value="31" lower_limit="21.2" upper_limit="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: After 13vPnC Dose 1 (n=95,120,215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2821" lower_limit="1891.1" upper_limit="4208.9"/>
                    <measurement group_id="O2" value="1031" lower_limit="671.3" upper_limit="1584.6"/>
                    <measurement group_id="O3" value="1609" lower_limit="1188.2" upper_limit="2178.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: Before 13vPnC Dose 1 (n=129,128,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="19.1" upper_limit="40.8"/>
                    <measurement group_id="O2" value="23" lower_limit="16.7" upper_limit="32.7"/>
                    <measurement group_id="O3" value="26" lower_limit="19.9" upper_limit="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: After 13vPnC Dose 1 (n=129,128,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506" lower_limit="381.9" upper_limit="671.7"/>
                    <measurement group_id="O2" value="390" lower_limit="275.2" upper_limit="552.8"/>
                    <measurement group_id="O3" value="445" lower_limit="355.7" upper_limit="555.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: Before 13vPnC Dose 1 (n=123,123,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7.6" upper_limit="15.5"/>
                    <measurement group_id="O2" value="14" lower_limit="9.5" upper_limit="20.1"/>
                    <measurement group_id="O3" value="12" lower_limit="9.5" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: After 13vPnC Dose 1 (n=123,123,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425" lower_limit="285.3" upper_limit="632.5"/>
                    <measurement group_id="O2" value="214" lower_limit="130.4" upper_limit="352.3"/>
                    <measurement group_id="O3" value="302" lower_limit="219.3" upper_limit="415.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: Before 13vPnC Dose 1 (n=118,125,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="9.3" upper_limit="22.0"/>
                    <measurement group_id="O2" value="7" lower_limit="5.3" upper_limit="9.0"/>
                    <measurement group_id="O3" value="10" lower_limit="7.6" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: After 13vPnC Dose 1 (n=118,125,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587" lower_limit="379.3" upper_limit="907.7"/>
                    <measurement group_id="O2" value="140" lower_limit="86.6" upper_limit="227.6"/>
                    <measurement group_id="O3" value="281" lower_limit="200.8" upper_limit="393.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.</description>
        <time_frame>Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the before and 1 month after 13vPnC Dose 1 blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the before and 1 month after 13vPnC Dose 1 blood draws for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n = 129, 127, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="6.97" upper_limit="13.81"/>
                    <measurement group_id="O2" value="12.2" lower_limit="8.84" upper_limit="16.84"/>
                    <measurement group_id="O3" value="10.9" lower_limit="8.65" upper_limit="13.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n = 126, 128, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3.72" upper_limit="6.30"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.22" upper_limit="5.30"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3.73" upper_limit="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n = 108, 119, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4" lower_limit="51.43" upper_limit="155.31"/>
                    <measurement group_id="O2" value="51.3" lower_limit="31.16" upper_limit="84.59"/>
                    <measurement group_id="O3" value="66.8" lower_limit="46.17" upper_limit="96.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n = 125, 122, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="9.56" upper_limit="21.67"/>
                    <measurement group_id="O2" value="21.7" lower_limit="14.55" upper_limit="32.32"/>
                    <measurement group_id="O3" value="17.6" lower_limit="13.25" upper_limit="23.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n = 99, 98, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="12.61" upper_limit="38.90"/>
                    <measurement group_id="O2" value="25.2" lower_limit="14.51" upper_limit="43.83"/>
                    <measurement group_id="O3" value="23.6" lower_limit="15.98" upper_limit="34.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n = 101, 120, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="8.12" upper_limit="23.45"/>
                    <measurement group_id="O2" value="9.1" lower_limit="5.91" upper_limit="13.95"/>
                    <measurement group_id="O3" value="11.0" lower_limit="7.87" upper_limit="15.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n = 110, 113, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="5.79" upper_limit="14.23"/>
                    <measurement group_id="O2" value="52.2" lower_limit="31.42" upper_limit="86.57"/>
                    <measurement group_id="O3" value="22.0" lower_limit="15.42" upper_limit="31.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n = 109, 117, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="9.71" upper_limit="28.47"/>
                    <measurement group_id="O2" value="17.8" lower_limit="10.53" upper_limit="30.18"/>
                    <measurement group_id="O3" value="17.2" lower_limit="11.87" upper_limit="25.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n = 107, 126, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="6.79" upper_limit="17.41"/>
                    <measurement group_id="O2" value="10.3" lower_limit="6.82" upper_limit="15.70"/>
                    <measurement group_id="O3" value="10.6" lower_limit="7.76" upper_limit="14.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n = 95, 120, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" lower_limit="35.25" upper_limit="130.73"/>
                    <measurement group_id="O2" value="41.6" lower_limit="24.59" upper_limit="70.26"/>
                    <measurement group_id="O3" value="51.6" lower_limit="34.27" upper_limit="77.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n = 129, 128, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="12.52" upper_limit="26.25"/>
                    <measurement group_id="O2" value="16.7" lower_limit="11.78" upper_limit="23.61"/>
                    <measurement group_id="O3" value="17.4" lower_limit="13.51" upper_limit="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n = 123, 123, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="24.56" upper_limit="62.05"/>
                    <measurement group_id="O2" value="15.5" lower_limit="9.77" upper_limit="24.65"/>
                    <measurement group_id="O3" value="24.6" lower_limit="17.69" upper_limit="34.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n = 118, 125, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="24.94" upper_limit="67.81"/>
                    <measurement group_id="O2" value="20.2" lower_limit="12.78" upper_limit="32.05"/>
                    <measurement group_id="O3" value="28.6" lower_limit="20.34" upper_limit="40.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</title>
        <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
        <time_frame>1 month after 13vPnC Dose 3, 1 month after 23vPS Dose</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 3 and after 23vPS Dose blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</title>
          <description>Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 3 and after 23vPS Dose blood draws for each treatment arm, respectively.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: After 13vPnC Dose 3 (n=128,127,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" lower_limit="3.53" upper_limit="4.73"/>
                    <measurement group_id="O2" value="3.94" lower_limit="3.22" upper_limit="4.82"/>
                    <measurement group_id="O3" value="4.01" lower_limit="3.54" upper_limit="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: After 23vPS Dose (n=128,127,255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" lower_limit="3.80" upper_limit="5.14"/>
                    <measurement group_id="O2" value="4.02" lower_limit="3.32" upper_limit="4.85"/>
                    <measurement group_id="O3" value="4.21" lower_limit="3.74" upper_limit="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: After 13vPnC Dose 3 (n=124,118,242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.27" upper_limit="1.75"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.87" upper_limit="1.26"/>
                    <measurement group_id="O3" value="1.25" lower_limit="1.11" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: After 23vPS Dose (n=124,118,242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.42" upper_limit="1.92"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.82" upper_limit="1.17"/>
                    <measurement group_id="O3" value="1.28" lower_limit="1.14" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: After 13vPnC Dose 3 (n=133,128,261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" lower_limit="2.79" upper_limit="3.87"/>
                    <measurement group_id="O2" value="3.19" lower_limit="2.59" upper_limit="3.93"/>
                    <measurement group_id="O3" value="3.24" lower_limit="2.84" upper_limit="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: After 23vPS Dose (n=133,128,261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" lower_limit="2.77" upper_limit="3.88"/>
                    <measurement group_id="O2" value="3.01" lower_limit="2.44" upper_limit="3.72"/>
                    <measurement group_id="O3" value="3.15" lower_limit="2.75" upper_limit="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: After 13vPnC Dose 3 (n=132,130,262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" lower_limit="4.02" upper_limit="5.57"/>
                    <measurement group_id="O2" value="5.54" lower_limit="4.64" upper_limit="6.63"/>
                    <measurement group_id="O3" value="5.12" lower_limit="4.54" upper_limit="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: After 23vPS Dose (n=132,130,262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" lower_limit="4.33" upper_limit="5.95"/>
                    <measurement group_id="O2" value="6.20" lower_limit="5.23" upper_limit="7.35"/>
                    <measurement group_id="O3" value="5.61" lower_limit="4.99" upper_limit="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: After 13vPnC Dose 3 (n=122,129,251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.20" lower_limit="6.99" upper_limit="9.61"/>
                    <measurement group_id="O2" value="7.07" lower_limit="5.75" upper_limit="8.69"/>
                    <measurement group_id="O3" value="7.60" lower_limit="6.67" upper_limit="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: After 23vPS Dose (n=122,129,251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.98" lower_limit="6.85" upper_limit="9.31"/>
                    <measurement group_id="O2" value="6.71" lower_limit="5.51" upper_limit="8.17"/>
                    <measurement group_id="O3" value="7.30" lower_limit="6.44" upper_limit="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: After 13vPnC Dose 3 (n=133,129,262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.25" lower_limit="10.31" upper_limit="14.55"/>
                    <measurement group_id="O2" value="8.29" lower_limit="6.78" upper_limit="10.13"/>
                    <measurement group_id="O3" value="10.10" lower_limit="8.84" upper_limit="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: After 23vPS Dose (n=133,129,262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.10" lower_limit="9.39" upper_limit="13.13"/>
                    <measurement group_id="O2" value="8.25" lower_limit="6.80" upper_limit="10.01"/>
                    <measurement group_id="O3" value="9.59" lower_limit="8.44" upper_limit="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: After 13vPnC Dose 3 (n=133,130,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" lower_limit="4.39" upper_limit="5.81"/>
                    <measurement group_id="O2" value="5.88" lower_limit="4.93" upper_limit="7.02"/>
                    <measurement group_id="O3" value="5.44" lower_limit="4.87" upper_limit="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: After 23vPS Dose (n=133,130,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" lower_limit="4.50" upper_limit="5.90"/>
                    <measurement group_id="O2" value="5.93" lower_limit="5.02" upper_limit="7.00"/>
                    <measurement group_id="O3" value="5.52" lower_limit="4.96" upper_limit="6.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: After 13vPnC Dose 3 (n=133,130,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" lower_limit="4.40" upper_limit="5.72"/>
                    <measurement group_id="O2" value="5.49" lower_limit="4.59" upper_limit="6.57"/>
                    <measurement group_id="O3" value="5.25" lower_limit="4.70" upper_limit="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: After 23vPS Dose (n=133,130,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" lower_limit="4.62" upper_limit="6.00"/>
                    <measurement group_id="O2" value="5.83" lower_limit="4.88" upper_limit="6.96"/>
                    <measurement group_id="O3" value="5.54" lower_limit="4.96" upper_limit="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: After 13vPnC Dose 3 (n=133,130,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.18" lower_limit="10.19" upper_limit="17.05"/>
                    <measurement group_id="O2" value="15.35" lower_limit="11.97" upper_limit="19.69"/>
                    <measurement group_id="O3" value="14.21" lower_limit="11.89" upper_limit="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: After 23vPS Dose (n=133,130,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.98" lower_limit="10.10" upper_limit="16.67"/>
                    <measurement group_id="O2" value="16.24" lower_limit="12.82" upper_limit="20.57"/>
                    <measurement group_id="O3" value="14.50" lower_limit="12.21" upper_limit="17.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: After 13vPnC Dose 3 (n=132,130,262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" lower_limit="3.21" upper_limit="4.59"/>
                    <measurement group_id="O2" value="5.17" lower_limit="4.25" upper_limit="6.28"/>
                    <measurement group_id="O3" value="4.45" lower_limit="3.90" upper_limit="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: After 23vPS Dose (n=132,130,262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" lower_limit="2.98" upper_limit="4.20"/>
                    <measurement group_id="O2" value="4.80" lower_limit="3.98" upper_limit="5.79"/>
                    <measurement group_id="O3" value="4.12" lower_limit="3.62" upper_limit="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: After 13vPnC Dose 3 (n=133,130,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.16" lower_limit="12.21" upper_limit="16.41"/>
                    <measurement group_id="O2" value="13.21" lower_limit="11.13" upper_limit="15.68"/>
                    <measurement group_id="O3" value="13.68" lower_limit="12.22" upper_limit="15.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: After 23vPS Dose (n=133,130,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.16" lower_limit="11.31" upper_limit="15.33"/>
                    <measurement group_id="O2" value="13.28" lower_limit="11.24" upper_limit="15.69"/>
                    <measurement group_id="O3" value="13.22" lower_limit="11.82" upper_limit="14.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: After 13vPnC Dose 3 (n=130,127,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" lower_limit="5.09" upper_limit="7.45"/>
                    <measurement group_id="O2" value="5.67" lower_limit="4.47" upper_limit="7.19"/>
                    <measurement group_id="O3" value="5.91" lower_limit="5.08" upper_limit="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: After 23vPS Dose (n=130,127,257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" lower_limit="5.65" upper_limit="8.14"/>
                    <measurement group_id="O2" value="5.84" lower_limit="4.62" upper_limit="7.39"/>
                    <measurement group_id="O3" value="6.30" lower_limit="5.44" upper_limit="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: After 13vPnC Dose 3 (n=132,129,261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" lower_limit="5.60" upper_limit="7.98"/>
                    <measurement group_id="O2" value="7.30" lower_limit="5.87" upper_limit="9.09"/>
                    <measurement group_id="O3" value="6.98" lower_limit="6.07" upper_limit="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: After 23vPS Dose (n=132,129,261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" lower_limit="5.05" upper_limit="7.11"/>
                    <measurement group_id="O2" value="7.03" lower_limit="5.69" upper_limit="8.70"/>
                    <measurement group_id="O3" value="6.49" lower_limit="5.66" upper_limit="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.</description>
        <time_frame>1 month after 13vPnC Dose 3, 1 month after 23vPS Dose</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 3 and after 23vPS Dose blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 3 and after 23vPS Dose blood draws for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n = 128, 127, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="1.01" upper_limit="1.16"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.96" upper_limit="1.08"/>
                    <measurement group_id="O3" value="1.05" lower_limit="1.00" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n = 124, 118, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="1.03" upper_limit="1.20"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.88" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.97" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n = 133, 128, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.94" upper_limit="1.05"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.90" upper_limit="0.99"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.94" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n = 132, 130, 262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="1.02" upper_limit="1.13"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.05" upper_limit="1.19"/>
                    <measurement group_id="O3" value="1.09" lower_limit="1.05" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n = 122, 129, 251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.92" upper_limit="1.04"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.91" upper_limit="0.99"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.93" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n = 133, 129, 262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.87" upper_limit="0.95"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.96" upper_limit="1.04"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.92" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n = 133, 130, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.97" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.95" upper_limit="1.06"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.98" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n = 133, 130, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="1.00" upper_limit="1.10"/>
                    <measurement group_id="O2" value="1.06" lower_limit="1.01" upper_limit="1.11"/>
                    <measurement group_id="O3" value="1.06" lower_limit="1.02" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n = 133, 130, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.91" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.99" upper_limit="1.13"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.97" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n = 132, 130, 262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.88" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.89" upper_limit="0.97"/>
                    <measurement group_id="O3" value="0.92" lower_limit="0.90" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n = 133, 130, 263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.89" upper_limit="0.97"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.96" upper_limit="1.05"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.94" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n = 130, 127, 257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="1.04" upper_limit="1.17"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.97" upper_limit="1.09"/>
                    <measurement group_id="O3" value="1.07" lower_limit="1.02" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n = 132, 129, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.86" upper_limit="0.94"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.91" upper_limit="1.02"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.89" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</title>
        <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a mcOPA assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>1 month after 13vPnC Dose 3, 1 month after 23vPS Dose</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 3 and after 23vPS Dose blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</title>
          <description>Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a mcOPA assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 3 and after 23vPS Dose blood draws for each treatment arm, respectively.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: After 13vPnC Dose 3 (n=131,125,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="53.4" upper_limit="93.0"/>
                    <measurement group_id="O2" value="67" lower_limit="50.2" upper_limit="90.6"/>
                    <measurement group_id="O3" value="69" lower_limit="56.4" upper_limit="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: After 23vPS Dose (n=131,125,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="76.6" upper_limit="130.3"/>
                    <measurement group_id="O2" value="66" lower_limit="49.0" upper_limit="90.2"/>
                    <measurement group_id="O3" value="82" lower_limit="66.9" upper_limit="100.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: After 13vPnC Dose 3 (n=132,128,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="94.6" upper_limit="136.7"/>
                    <measurement group_id="O2" value="78" lower_limit="61.3" upper_limit="98.7"/>
                    <measurement group_id="O3" value="94" lower_limit="81.1" upper_limit="109.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: After 23vPS Dose (n=132,128,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="123.9" upper_limit="177.3"/>
                    <measurement group_id="O2" value="103" lower_limit="81.6" upper_limit="130.9"/>
                    <measurement group_id="O3" value="124" lower_limit="107.0" upper_limit="144.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: After 13vPnC Dose 3 (n=127,126,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3213" lower_limit="2698.5" upper_limit="3826.6"/>
                    <measurement group_id="O2" value="1888" lower_limit="1427.3" upper_limit="2498.1"/>
                    <measurement group_id="O3" value="2466" lower_limit="2087.0" upper_limit="2913.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: After 23vPS Dose (n=127,126,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3553" lower_limit="2984.9" upper_limit="4229.7"/>
                    <measurement group_id="O2" value="1831" lower_limit="1366.0" upper_limit="2453.7"/>
                    <measurement group_id="O3" value="2554" lower_limit="2146.3" upper_limit="3038.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: After 13vPnC Dose 3 (n=129,124,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="197.0" upper_limit="370.1"/>
                    <measurement group_id="O2" value="143" lower_limit="97.5" upper_limit="209.6"/>
                    <measurement group_id="O3" value="198" lower_limit="154.2" upper_limit="253.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5: After 23vPS Dose (n=129,124,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378" lower_limit="276.5" upper_limit="516.9"/>
                    <measurement group_id="O2" value="186" lower_limit="130.9" upper_limit="264.4"/>
                    <measurement group_id="O3" value="267" lower_limit="210.6" upper_limit="338.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: After 13vPnC Dose 3 (n=132,127,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8011" lower_limit="6580.0" upper_limit="9752.1"/>
                    <measurement group_id="O2" value="2956" lower_limit="2240.1" upper_limit="3900.3"/>
                    <measurement group_id="O3" value="4913" lower_limit="4109.7" upper_limit="5873.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A: After 23vPS Dose (n=132,127,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7236" lower_limit="5936.2" upper_limit="8819.4"/>
                    <measurement group_id="O2" value="2707" lower_limit="2060.8" upper_limit="3556.3"/>
                    <measurement group_id="O3" value="4468" lower_limit="3743.3" upper_limit="5333.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: After 13vPnC Dose 3 (n=130,126,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7102" lower_limit="5853.9" upper_limit="8615.8"/>
                    <measurement group_id="O2" value="3666" lower_limit="2720.7" upper_limit="4940.5"/>
                    <measurement group_id="O3" value="5129" lower_limit="4283.9" upper_limit="6141.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B: After 23vPS Dose (n=130,126,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6652" lower_limit="5460.8" upper_limit="8102.8"/>
                    <measurement group_id="O2" value="3324" lower_limit="2496.6" upper_limit="4426.2"/>
                    <measurement group_id="O3" value="4728" lower_limit="3961.1" upper_limit="5643.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: After 13vPnC Dose 3 (n=131,125,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4640" lower_limit="3915.9" upper_limit="5497.9"/>
                    <measurement group_id="O2" value="2821" lower_limit="2283.2" upper_limit="3484.4"/>
                    <measurement group_id="O3" value="3639" lower_limit="3171.6" upper_limit="4174.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F: After 23vPS Dose (n=131,125,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5260" lower_limit="4470.4" upper_limit="6189.9"/>
                    <measurement group_id="O2" value="3027" lower_limit="2455.7" upper_limit="3731.3"/>
                    <measurement group_id="O3" value="4016" lower_limit="3508.3" upper_limit="4597.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: After 13vPnC Dose 3 (n=127,125,252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4501" lower_limit="3606.4" upper_limit="5618.0"/>
                    <measurement group_id="O2" value="1980" lower_limit="1394.6" upper_limit="2811.7"/>
                    <measurement group_id="O3" value="2995" lower_limit="2424.2" upper_limit="3700.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V: After 23vPS Dose (n=127,125,252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5114" lower_limit="4090.6" upper_limit="6393.0"/>
                    <measurement group_id="O2" value="2037" lower_limit="1452.6" upper_limit="2857.6"/>
                    <measurement group_id="O3" value="3240" lower_limit="2629.5" upper_limit="3991.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: After 13vPnC Dose 3 (n=127,126,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4023" lower_limit="3317.5" upper_limit="4879.5"/>
                    <measurement group_id="O2" value="1431" lower_limit="1115.7" upper_limit="1836.1"/>
                    <measurement group_id="O3" value="2405" lower_limit="2030.8" upper_limit="2847.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14: After 23vPS Dose (n=127,126,253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4718" lower_limit="3861.6" upper_limit="5764.9"/>
                    <measurement group_id="O2" value="1620" lower_limit="1284.5" upper_limit="2043.0"/>
                    <measurement group_id="O3" value="2771" lower_limit="2346.9" upper_limit="3270.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: After 13vPnC Dose 3 (n=129,121,250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5455" lower_limit="4401.5" upper_limit="6761.4"/>
                    <measurement group_id="O2" value="1667" lower_limit="1172.5" upper_limit="2370.8"/>
                    <measurement group_id="O3" value="3074" lower_limit="2479.2" upper_limit="3810.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C: After 23vPS Dose (n=129,121,250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6468" lower_limit="5341.1" upper_limit="7832.2"/>
                    <measurement group_id="O2" value="1835" lower_limit="1328.1" upper_limit="2535.5"/>
                    <measurement group_id="O3" value="3515" lower_limit="2878.5" upper_limit="4292.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: After 13vPnC Dose 3 (n=131,125,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1021" lower_limit="837.5" upper_limit="1245.6"/>
                    <measurement group_id="O2" value="603" lower_limit="456.7" upper_limit="796.3"/>
                    <measurement group_id="O3" value="790" lower_limit="665.2" upper_limit="937.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A: After 23vPS Dose (n=131,125,256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1244" lower_limit="1012.1" upper_limit="1529.5"/>
                    <measurement group_id="O2" value="691" lower_limit="531.0" upper_limit="898.6"/>
                    <measurement group_id="O3" value="933" lower_limit="788.2" upper_limit="1105.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: After 13vPnC Dose 3 (n=126,117,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1166" lower_limit="884.3" upper_limit="1537.7"/>
                    <measurement group_id="O2" value="564" lower_limit="375.0" upper_limit="848.1"/>
                    <measurement group_id="O3" value="822" lower_limit="642.8" upper_limit="1051.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F: After 23vPS Dose (n=126,117,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1696" lower_limit="1296.5" upper_limit="2217.5"/>
                    <measurement group_id="O2" value="790" lower_limit="547.5" upper_limit="1139.7"/>
                    <measurement group_id="O3" value="1174" lower_limit="934.2" upper_limit="1474.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: After 13vPnC Dose 3 (n=128,126,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2346" lower_limit="1883.3" upper_limit="2922.6"/>
                    <measurement group_id="O2" value="650" lower_limit="435.3" upper_limit="969.9"/>
                    <measurement group_id="O3" value="1241" lower_limit="976.6" upper_limit="1576.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F: After 23vPS Dose (n=128,126,254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2595" lower_limit="2143.3" upper_limit="3141.5"/>
                    <measurement group_id="O2" value="580" lower_limit="386.1" upper_limit="871.8"/>
                    <measurement group_id="O3" value="1234" lower_limit="970.1" upper_limit="1570.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.</description>
        <time_frame>1 month after 13vPnC Dose 3, 1 month after 23vPS Dose</time_frame>
        <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 3 and after 23vPS Dose blood draws for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.</description>
          <population>Evaluable immunogenicity population. Here “N” (number of participants analyzed) signifies those participants who were evaluable for this measure and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both 1 month after 13vPnC Dose 3 and after 23vPS Dose blood draws for each treatment arm, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n = 131, 125, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.23" upper_limit="1.63"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.86" upper_limit="1.13"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.08" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n = 132, 128, 260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.15" upper_limit="1.48"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.17" upper_limit="1.51"/>
                    <measurement group_id="O3" value="1.3" lower_limit="1.20" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n = 127, 126, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.04" upper_limit="1.18"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.87" upper_limit="1.09"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.97" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n = 129, 124, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.15" upper_limit="1.71"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.13" upper_limit="1.50"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.20" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n = 132, 127, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.85" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.86" upper_limit="0.97"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.87" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n = 130, 126, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.87" upper_limit="1.01"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.79" upper_limit="1.04"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.86" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n = 131, 125, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.06" upper_limit="1.21"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.93" upper_limit="1.23"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.02" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n = 127, 125, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.05" upper_limit="1.23"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.84" upper_limit="1.27"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.97" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n = 127, 126, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.07" upper_limit="1.28"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.03" upper_limit="1.24"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.08" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n = 129, 121, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.04" upper_limit="1.35"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.92" upper_limit="1.31"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.03" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n = 131, 125, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.11" upper_limit="1.34"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.03" upper_limit="1.27"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.10" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n = 126, 117, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.25" upper_limit="1.69"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.14" upper_limit="1.72"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.26" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n = 128, 126, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.96" upper_limit="1.28"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.81" upper_limit="0.98"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.91" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1</title>
        <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters (cm) for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged greater than (&gt;) 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Report of severe swelling was confirmed as data entry error.</description>
        <time_frame>Within 14 days after 13vPnC Dose 1</time_frame>
        <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any local reaction and “n” signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1</title>
          <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters (cm) for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged greater than (&gt;) 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Report of severe swelling was confirmed as data entry error.</description>
          <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any local reaction and “n” signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n = 92, 88, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n = 91, 88, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n = 85, 88, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n = 84, 88, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n = 97, 94, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="9.6"/>
                    <measurement group_id="O3" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n = 91, 93, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n = 92, 89, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n = 84, 88, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Any (n = 117, 121, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4"/>
                    <measurement group_id="O2" value="62.8"/>
                    <measurement group_id="O3" value="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Mild (n = 112, 116, 228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="56.0"/>
                    <measurement group_id="O3" value="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Moderate (n = 94, 94, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="18.1"/>
                    <measurement group_id="O3" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Severe (n = 86, 89, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2</title>
        <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
        <time_frame>Within 14 days after 13vPnC Dose 2</time_frame>
        <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any local reaction and “n” signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2</title>
          <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
          <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any local reaction and “n” signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n = 101, 86, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n = 100, 86, 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n = 95, 85, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n = 93, 85, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n = 103, 88, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n = 102, 88, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n = 99, 85, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n = 93, 85, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Any (n = 117, 119, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="79.8"/>
                    <measurement group_id="O3" value="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Mild (n = 110, 117, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="72.6"/>
                    <measurement group_id="O3" value="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Moderate (n= 103, 96, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="27.1"/>
                    <measurement group_id="O3" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Severe (n = 93, 86, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="3.5"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3</title>
        <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
        <time_frame>Within 14 days after 13vPnC Dose 3</time_frame>
        <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any local reaction and “n” signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3</title>
          <description>Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to &lt;12 years and 2.5 to 5.0 cm for participants aged &gt;12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to &lt;12 years and 5.1 to 10.0 cm for participants aged &gt;12 years); Severe (&gt;7 cm for participants aged 6 to &lt;12 years and &gt;10 cm for participants aged &gt;12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).</description>
          <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any local reaction and “n” signifies participants with known values for specified local reaction. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n = 84, 70, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n = 83, 70, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n = 82, 70, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n = 80, 70, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n = 89, 71, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n = 86, 71, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n = 84, 70, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n = 80, 70, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Any (n = 104, 109, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9"/>
                    <measurement group_id="O2" value="69.7"/>
                    <measurement group_id="O3" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Mild (n = 96, 105, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="63.8"/>
                    <measurement group_id="O3" value="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Moderate (n = 89, 78, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Injection Site: Severe (n = 83, 73, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1</title>
        <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C except 2 participants and all reporting of severe vomiting, after 13vPnC Dose 1, were confirmed as data entry errors.</description>
        <time_frame>Within 14 days after 13vPnC Dose 1</time_frame>
        <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any systemic event and “n” signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1</title>
          <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C except 2 participants and all reporting of severe vomiting, after 13vPnC Dose 1, were confirmed as data entry errors.</description>
          <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any systemic event and “n” signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38 degrees C (n= 94, 95, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38, &lt;38.5 degrees C (n = 87, 92, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5, &lt;39 degrees C (n = 85, 89, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39, =&lt;40 degrees C (n = 86, 88, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n = 88, 93, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n = 111, 119, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n = 105, 113, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="51.3"/>
                    <measurement group_id="O3" value="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n = 96, 99, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0"/>
                    <measurement group_id="O2" value="28.3"/>
                    <measurement group_id="O3" value="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n = 86, 92, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n = 107, 113, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="61.1"/>
                    <measurement group_id="O3" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n = 100, 109, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0"/>
                    <measurement group_id="O2" value="57.8"/>
                    <measurement group_id="O3" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n = 94, 97, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n = 87, 89, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="9.0"/>
                    <measurement group_id="O3" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (n = 89, 91, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n = 89, 91, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n = 84, 88, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n = 85, 88, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (n = 94, 105, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5"/>
                    <measurement group_id="O2" value="34.3"/>
                    <measurement group_id="O3" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n = 92, 104, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="29.8"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n = 86, 91, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n = 85, 88, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Any (n = 108, 118, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="62.7"/>
                    <measurement group_id="O3" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Mild (n = 103, 110, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                    <measurement group_id="O2" value="56.4"/>
                    <measurement group_id="O3" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Moderate (n = 89, 98, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Severe (n = 86, 91, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Any (n = 100, 105, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Mild (n = 98, 101, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="36.6"/>
                    <measurement group_id="O3" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Moderate (n = 89, 95, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Severe (n = 84, 91, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="4.4"/>
                    <measurement group_id="O3" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Pain (n = 101, 96, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="24.0"/>
                    <measurement group_id="O3" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Fever (n=112, 107, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6"/>
                    <measurement group_id="O2" value="39.3"/>
                    <measurement group_id="O3" value="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2</title>
        <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C and all reporting of severe vomiting, after 13vPnC Dose 2, were confirmed as data entry errors.</description>
        <time_frame>Within 14 days after 13vPnC Dose 2</time_frame>
        <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any systemic event and “n” signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2</title>
          <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C and all reporting of severe vomiting, after 13vPnC Dose 2, were confirmed as data entry errors.</description>
          <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any systemic event and “n” signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38 degrees C (n= 102, 88, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="11.4"/>
                    <measurement group_id="O3" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38, &lt;38.5 degrees C (n = 96, 87, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5, &lt;39 degrees C (n = 98, 85, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39, =&lt;40 degrees C (n = 97, 87, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n = 95, 85, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n = 106, 105, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0"/>
                    <measurement group_id="O2" value="48.6"/>
                    <measurement group_id="O3" value="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n = 104, 103, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="42.7"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n = 96, 88, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="21.6"/>
                    <measurement group_id="O3" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n = 95, 88, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="5.7"/>
                    <measurement group_id="O3" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n = 101, 106, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="49.1"/>
                    <measurement group_id="O3" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n = 97, 102, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="40.2"/>
                    <measurement group_id="O3" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n = 97, 93, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n = 94, 88, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (n = 96, 89, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n = 94, 89, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="9.0"/>
                    <measurement group_id="O3" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n = 94, 85, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n = 94, 85, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (n = 95, 95, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="26.3"/>
                    <measurement group_id="O3" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n = 94, 93, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n = 93, 87, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n = 94, 85, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Any (n = 112, 104, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="52.9"/>
                    <measurement group_id="O3" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Mild (n = 105, 103, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="46.6"/>
                    <measurement group_id="O3" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Moderate (n = 100, 91, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="20.9"/>
                    <measurement group_id="O3" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Severe (n = 95, 85, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Any (n = 106, 95, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4"/>
                    <measurement group_id="O2" value="34.7"/>
                    <measurement group_id="O3" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Mild (n = 100, 93, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Moderate (n = 99, 89, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="12.4"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Severe (n = 94, 85, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Pain (n = 100, 91, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Fever (n=102, 96, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3</title>
        <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C except 1 participant and all reporting of severe vomiting, after 13vPnC Dose 3, were confirmed as data entry errors.</description>
        <time_frame>Within 14 days after 13vPnC Dose 3</time_frame>
        <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any systemic event and “n” signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC, 23vPS (Pediatric Participants)</title>
            <description>Participants older than or equal to [&gt;=] 6 to less than [&lt;] 18 years of age (pediatric participants) received 3 doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23-valent pneumococcal polysaccharide vaccine (23vPS) intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC, 23vPS (Adult Participants)</title>
            <description>Participants &gt;=18 years of age (adult participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC, 23vPS (All Participants)</title>
            <description>Participants &gt;=6 years of age (all participants) received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3</title>
          <description>Specific systemic events (fever &gt;=38 degrees Celsius[C], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (&gt;2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (&gt;=6 loose stools in 24 hours). All reporting of fever &gt;40 degrees C except 1 participant and all reporting of severe vomiting, after 13vPnC Dose 3, were confirmed as data entry errors.</description>
          <population>Safety population. Here “N” (number of participants analyzed) signifies participants with known values for any systemic event and “n” signifies participants with known values for specified systemic event. Participants may be represented in more than 1 category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38 degrees C (n= 85, 73, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="11.0"/>
                    <measurement group_id="O3" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38, &lt;38.5 degrees C (n = 82, 73, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5, &lt;39 degrees C (n = 81, 72, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39, =&lt;40 degrees C (n = 82, 70, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n = 83, 70, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n = 92, 91, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="47.3"/>
                    <measurement group_id="O3" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n = 89, 88, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                    <measurement group_id="O2" value="39.8"/>
                    <measurement group_id="O3" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n = 83, 80, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n = 83, 73, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n = 88, 89, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="46.1"/>
                    <measurement group_id="O3" value="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n = 84, 87, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n = 83, 77, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="19.5"/>
                    <measurement group_id="O3" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n = 82, 72, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (n = 85, 74, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n = 84, 72, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n = 82, 73, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n = 81, 72, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (n = 81, 81, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="28.4"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n = 81, 79, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n = 80, 73, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n = 81, 73, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Any (n = 99, 92, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4"/>
                    <measurement group_id="O2" value="47.8"/>
                    <measurement group_id="O3" value="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Mild (n = 93, 89, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="37.1"/>
                    <measurement group_id="O3" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Moderate (n = 85, 78, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Pain: Severe (n = 84, 72, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Any (n = 91, 83, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="32.5"/>
                    <measurement group_id="O3" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Mild (n = 88, 82, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Moderate (n = 82, 77, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain: Severe (n = 81, 71, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Pain (n = 90, 79, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Medication to Treat Fever (n = 89, 75, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Informed consent through 6-month follow-up after 13vPnC Dose 3. Local reactions and systemic events assessed within 14 days after: 13vPnC Dose 1 (Day 1); 13vPnC Dose 2 (28-42 days after 13vPnC Dose 1); and 13vPnC Dose 3 (28-42 days after 13vPnC Dose 2)</time_frame>
      <desc>Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may=serious for 1 subject and=non-serious for another subject or subject may have experienced both a serious and non-serious episode of same event. AEs/SAEs=non-systematic assessment; local reactions and systemic events=systematic assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prior 13vPnC Dose 1</title>
          <description>Participants &gt;=6 years of age (all participants) who received at least 1 of 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose), assessed between signing of informed consent form and before 13vPnC Dose 1.</description>
        </group>
        <group group_id="E2">
          <title>13vPnC Dose 1</title>
          <description>Participants &gt;=6 years of age (all participants) who received a single dose of 0.5 mL of 13vPnC intramuscularly on Day 1 (13vPnC Dose 1), assessed between 13vPnC Dose 1 and before 13vPnC Dose 2.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Dose 2</title>
          <description>Participants &gt;=6 years of age (all participants) who received a single dose of 0.5 mL of 13vPnC intramuscularly 1 month after 13vPnC Dose 1 (13vPnC Dose 2), assessed between 13vPnC Dose 2 and before 13vPnC Dose 3.</description>
        </group>
        <group group_id="E4">
          <title>13vPnC Dose 3</title>
          <description>Participants &gt;=6 years of age (all participants) who received a single dose of 0.5 mL of 13vPnC intramuscularly 1 month after 13vPnC Dose 2 (13vPnC Dose 3), assessed between 13vPnC Dose 3 and before 23vPS Dose.</description>
        </group>
        <group group_id="E5">
          <title>23vPS Dose</title>
          <description>Participants &gt;=6 years of age (all participants) who received a single dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose), assessed between 23vPS Dose and before 23vPS Dose blood draw 1 month after 23vPS Dose.</description>
        </group>
        <group group_id="E6">
          <title>Follow-up</title>
          <description>Participants &gt;=6 years of age (all participants) who received 3 doses of 0.5 mL of 13vPnC intramuscularly 1 month apart, followed by 1 dose of 0.5 mL of 23vPS intramuscularly 1 month after 13vPnC Dose 3 (23vPS Dose), assessed from 23vPS blood draw to the 6-month follow-up telephone contact after 13vPnC Dose 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="137" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Salivary gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vaccination site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (≥38°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="190"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (≥38°C but &lt;38.5°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (≥38.5°C but &lt;39°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (≥39°C but ≤40°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (&gt;40°C)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>All reporting of fever &gt;40 degrees C except 2 participants in 13vPnC Dose 1 and 1 participant in 13vPnC Dose 3 were confirmed as data entry errors.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="211"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="207"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="207"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="171"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="190"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="160"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="185"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>All reporting of severe vomiting were confirmed as data entry errors.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="190"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="160"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="177"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Muscle pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="191"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Muscle pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="213"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Muscle pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Muscle pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Joint pain (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Joint pain (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="193"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Joint pain (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="188"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Joint pain (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="160"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="190"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain at injection site (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="166" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="131" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain at injection site (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="228"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain at injection site (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="199"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="167"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain at injection site (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

